Abstract Body

The AMP (Antibody Mediated Prevention) trial was the first study to show that a broadly neutralizing antibody (bnAb), VRC01, could prevent HIV-1 acquisition. However, this protection was incomplete, with VRC01 only blocking highly sensitive viruses. Here we will explore innate and selected resistance in breakthrough infections from this trial. Using an updated virus panel, we will place these results in the context of other clinically relevant bnAb interventions. In the AMP trial, VRC01 was found to prevent infection of viruses with IC80 against the VRC01 clinical product < 1 ug/ml, and it was estimated that a serum titre of 1:200 against circulating viruses was required for 90% prevention efficacy. To further examine the genetic barrier to resistance we used a novel PacBio deep sequencing approach to generate hundreds of viral envelope sequences per individual, at two timepoints. A subset of these sequences were cloned and evaluated for their neutralization sensitivity to a panel of bnAbs using a pseudovirus assay. In participants from HVTN703/HPTN081 AMP, which evaluated VRC01 to prevent infection in women from sub-saharan Africa, we demonstrated that the genetic bottleneck associated with transmission is more complex than previously estimated: we identified evidence of infection with low frequency variants; and in a subset of individuals infected with multiple viruses, we found that it was more common to harbour viruses that differed more than 2.5 fold in VRC01-neutralization sensitivity in the VRC01 arm compared to the placebo arm. This discordant VRC01 phenotype was due to both infection with viruses with a mixed phenotype, as well as evolution of resistance post-infection. While HIV-1 has diversified over the duration of the epidemic, this has had limited impact on sensitivity to bnAbs currently being evaluated in clinical trials. Thus, AMP informed the field in two important ways: firstly it showed that using bnAbs to prevent infection was possible and secondly it identified that VRC01 neutralization titre was a strong predictor of acquisition risk. We find evidence that VRC01 is not only exerting a selective pressure on the virus both prior to acquisition, but also post-acquisition. Although HIV-1 is diversifying as the epidemic progresses, there is limited antigenic drift supporting the use of combination bnAbs which can combat diversity and overcome the limitations of a single bnAb approach.